Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
SABCS 2024 | San Antonio, TX
Dec 10 - 13, 2024
Poster
Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors and EverolimusSABCS 2024 | San Antonio, TX
Dec 10 - 13, 2024
Poster
Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor Degrader, Plus Palbociclib in CDK4/6 Inhibitor–Resistant Wild-Type and Estrogen Receptor Y537S–Mutant Patient-Derived Xenograft ModelsACoP 2024 | Phoenix, AZ
Nov 10 - 13, 2024
Poster
Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult ParticipantsAACR-iCML 2024 | Philadelphia, PA
Jun 19 - 22, 2024
Poster
Trial in Progress: Phase 1 Study of ARV-393, a PROteolysis TArgeting Chimera (PROTAC) B-Cell Lymphoma 6 Degrader, in Advanced Non-Hodgkin LymphomaBiennial International LRRK2 Meeting 2024 | Crete, Greece
Jun 18 - 21, 2024
Presentation
Development of Potent, Orally Bioavailable PROTAC® LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for NeurodegenerationEHA 2024 | Madrid, Spain
Jun 13 - 16, 2024
Poster
Oral ARV-393 is a BCL6 Degrading PROTAC® Efficacious as a Monotherapy in B-Cell Lymphoma Preclinical CDX and PDX ModelsASCO 2024 | Chicago, IL
May 31 - Jun 4, 2024
Presentation
ARV-766, A PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Initial Results of a Phase 1/2 StudyASCO 2024 | Chicago, IL
May 31 - Jun 4, 2024
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast CancerESMO-BC 2024 | Berlin, Germany
May 15 - 17, 2024